Trazodone and Alzheimer's Sleep: Four Trial Checks

A caregiver may notice fewer nighttime calls while a wrist monitor records something different. Before a prescribing appointment, write down which change matters: sleeping longer, waking less often or needing less overnight help.

Check who reached the analysis

The Brazilian trial randomized 36 people with probable Alzheimer’s disease and sleep disturbances. They lived at home with overnight caregivers. Thirty were analyzed, after two clinical withdrawals and four failed recordings.¹

Their mean age was 81.¹

Treatment was trazodone 50 mg at 10 p.m. or placebo for two weeks.¹

Read the minutes with their uncertainty

Wrist actigraphy estimated 42.46 extra nighttime minutes versus placebo, adjusted for baseline (95% confidence interval 0.9–84.0). This was movement-based measurement, not a sleep-laboratory recording.¹

Caregivers rated sleep better in 10/15 versus 9/15; that difference was not statistically significant. Two-week cognitive testing cannot establish long-term safety or disease benefit.¹

Among analyzed participants, mild adverse events were reported in 4/15 versus 6/15. This small comparison cannot rule out uncommon harms.¹

CNPq supported the study; Apsen supplied tablets and placebo. Authors reported no financial conflicts.¹

Review safety beyond the small trial

The current US label indicates trazodone for major depression in adults. Sleep treatment is off-label. It warns about sedation, fainting on standing and low sodium, which can cause confusion and unsteadiness. Older adults and people taking diuretics have greater low-sodium risk.²

It also warns about heart-rhythm problems, including QT prolongation. Ask the prescriber to review heart history and the complete medicine list, including other sedatives and medicines affecting serotonin or heart rhythm. MAO inhibitors are contraindicated with trazodone and within the specified washout period.²

The label recommends gradual dose reduction rather than abrupt stopping whenever possible. Ask for instructions before changing an existing prescription.²

Include care outside the prescription

NICE’s³ dementia guidance in England advises considering a personalized combination of sleep-hygiene education, daylight, exercise and activities suited to the person. That recommendation does not select trazodone.³

Agree who will record overnight events and when the clinician will review benefit and unwanted effects. Bring both the person’s experience and the caregiver’s observations, identifying which is which.

The Make the Account Specific section in Did I Do That in My Sleep? distinguishes someone’s observation from a device estimate. It also asks about timing, daytime effects and changes after treatment. Those distinctions can keep an appointment focused on what has actually happened.